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OBJECTIVES The purpose of the study was to evaluate the lower extremity vascular responsiveness to
metabolic stimuli in patients with heart failure and to determine whether these responses
improve acutely after intensive medical therapy.
BACKGROUND Metabolic regulation of vascular tone is an important determinant of blood flow, and may be
abnormal in heart failure.
METHODS The leg blood flow responses were measured in 11 patients with nonedematous class III–IV
heart failure before and after inpatient medical therapy and in 10 normal subjects. Venous
occlusion plethysmography was used to measure peak blood flow and total hyperemia in the
calf after arterial occlusion and also after isotonic ankle exercise. Measurements were repeated
following short-term inpatient treatment with vasodilators and diuretics administered to
decrease right atrial pressure (18 6 2 to 7 6 1 mm Hg), pulmonary wedge pressure (32 6
3 to 15 6 2 mm Hg), and systemic vascular resistance (1581 6 200 to 938 6 63
dyneszszcm25, all p , 0.02).
RESULTS Leg blood flow at rest, after exercise, and during reactive hyperemia was less in heart failure
patients than in control subjects. Resting leg blood flow did not increase significantly after
medical therapy, but peak flow after the high level of exercise increased by 59% (p 5 0.009).
Total hyperemic volume in the recovery period increased by 73% (p 5 0.03). Similarly, the
peak leg blood flow response to ischemia increased by 88% (p 5 0.04), whereas hyperemic
volume rose by 98% (p 5 0.1).
CONCLUSIONS The calf blood flow responses to metabolic stimuli are blunted in patients with severe heart
failure, and improve rapidly with intensive medical therapy. (J Am Coll Cardiol 1999;33:
743–9) © 1999 by the American College of Cardiology
In clinical heart failure, hemodynamic alterations lead to an
inadequate supply of nutrient blood flow to metabolically
active tissues and contribute to exercise intolerance (1,2).
Inability to increase blood flow to accommodate metabolic
requirements may be attributed, in part, to impaired vascu-
lar reactivity in these patients. Many studies have found that
peripheral vasodilation in heart failure patients is impaired
in response to a variety of pharmacologic stimuli including
nitric oxide donors, substance P, phentolamine, and mus-
carinic agonists (3–9). Moreover, regional blood flow re-
sponses to specific metabolic stimuli, such as exercise and
ischemia, are abnormal both in experimental models of
heart failure and in patients with heart failure (1,2,9–17).
Heart transplantation, physical training, and diuresis alone
have not been found to normalize blood flow responses to
metabolic stimuli in this population (18–21). Whether
intensive medical treatment with vasodilators and diuretics
titrated to normalize resting hemodynamics can achieve this
physiologic objective is not known.
Accordingly, the purpose of this study was to evaluate
vascular responsiveness to exercise in patients with severe
heart failure, and to determine whether these responses
improve after short-term medical therapy. Leg exercise is a
common source of symptoms during daily activities in the
heart-failure population; therefore, we purposefully investi-
gated vascular function in the lower extremity. Calf vasore-
activity was studied before and after intensive, inpatient
medical therapy designed to rapidly improve cardiac hemo-
dynamics.
METHODS
Study population. Participants in the study included 11
patients with heart failure, eight men and three women,
aged 49 6 3 years (mean 6 SE). All were admitted to the
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hospital for intensive medical therapy. Each patient had
symptoms of heart failure for more than 6 months. Nine
patients were New York Heart Association (NYHA) class
IV, and two patients were NYHA class III. The average left
ventricular ejection fraction was 21 6 1%, determined by
echocardiography. Two subjects had no detectable mitral
regurgitation, two patients had mild mitral regurgitation,
four had mild to moderate regurgitation, and three had
moderate regurgitation as estimated by the color flow
Doppler technique (22). In the six patients able to perform
an exercise test, the average peak oxygen consumption was
9.3 ml/min/kg. The etiology of left ventricular dysfunction
was coronary artery disease in five patients, valvular disease
in one patient, and idiopathic cardiomyopathy in five
patients. Four heart-failure subjects had diabetes mellitus.
These were treated with insulin and maintained stable
glucose levels less than 200 mg/dl. Two of the three female
heart-failure patients were postmenopausal; they were not
taking hormone replacement therapy. Exclusion criteria
included detectable peripheral edema, malignant ventricular
arrhythmias, angina, electrocardiographic (ECG) evidence
of myocardial ischemia during exercise, hypertension, hy-
percholesterolemia, poorly controlled diabetes mellitus,
drug or tobacco use within a year of the study, and use of
nonsteroidal anti-inflammatory agents. Study participants
also included ten healthy, nonsmoking subjects, five men
and five women, mean age 52 6 2 years (p 5 0.41 vs.
heart-failure subjects) who were recruited from the local
community via newspaper advertisements. All of these
subjects had a normal medical history and physical exami-
nation. Three of five female control subjects were post-
menopausal; they were not taking hormone replacement
therapy. All participants gave written, informed, voluntary
consent. The study was approved by the Human Research
Committee of Brigham and Women’s Hospital.
Experimental protocol. Each participant was studied in
the postabsorptive state in a quiet, 22°C temperature-
controlled room with minimal auditory and visual stimula-
tion. Calf blood flow was measured by venous occlusion
mercury-in-silastic strain gauge plethysmography (Hokan-
son EC4, DE Hokanson, Bellevue, Washington). The calf
was positioned 15 cm above the level of the right atrium.
Venous occlusion was attained by rapid inflation of a
sphygmomanometric cuff on the thigh. The cuff was in-
flated suddenly to the lowest pressure necessary to obtain
the maximum rate of increase in calf circumference; this
pressure was determined at the beginning of each study.
Average venous occlusion pressure was 35 6 5 mm Hg. Calf
blood flow was derived from the rate of change in calf
circumference during venous occlusion, and is expressed in
ml/min/100 ml tissue. Foot blood flow was excluded by
inflation of an ankle cuff to 50 mm Hg above systolic
pressure during all measurements. Blood pressure was mea-
sured every 3 min, and heart rate and ECG were continu-
ously monitored. All calf blood flow measurements were
recorded on a Gould physiologic recorder (Gould, Cleve-
land, Ohio).
The baseline calf blood flow determination consisted of at
least five measurements made at 15-s intervals while the
subject was resting. Baseline measurements were repeated
until stability was assured. Each subject then performed
ankle flexion exercise for 2 min through a 60° range of
motion at two rates, 30 and 60 cycles/min, monitored by a
metronome. Calf blood flow measurements commenced
immediately following cessation of each exercise period and
continued every five s for two min, then every 15 s for an
additional two min. Ten minutes after these measurements,
blood flow measurements were made at rest to assure that
flow had returned to the baseline. The exercise protocol was
then repeated. Measurements derived from these two peri-
ods of exercise were subsequently averaged for each exercise
rate. After restoration of basal calf blood flow, ischemia-
induced reactive hyperemia was measured following release
of a sphygmomanometric cuff, which had been inflated on
the lower thigh to suprasystolic pressures for five min. Calf
blood flow was measured immediately following cuff defla-
tion, then every five s for two min, and then every 15 s for
another 2 min.
Medical therapy. In the normal subjects, calf blood flow
measurements were made on one occasion. In the heart-
failure patients, calf vascular function was studied before
and after intensive medical therapy. Within 24 h of the first
vascular study, a Swan-Ganz catheter was inserted into an
internal jugular or subclavian vein, using the modified
Seldinger technique, under sterile conditions and local
anaesthetic (1% lidocaine). Baseline measurements were
made to document systemic blood pressure, right atrial
pressure, pulmonary capillary wedge pressure, pulmonary
artery pressure, cardiac output, systemic vascular resistance,
and pulmonary vascular resistance. A combination of nitro-
prusside and diuretics was used to attain the following
predetermined, hemodynamic objectives: right atrial pres-
sure #7 mm Hg, pulmonary capillary wedge pressure
#15 mm Hg, and systemic vascular resistance between 1000
and 1200 dyneszszcm25, while maintaining a systolic blood
pressure $80 mm Hg (23). One subject was monitored with
central venous pressures only.
Once these goals were achieved, nitroprusside was
weaned and oral vasodilators were added in doses to
maintain the hemodynamic objectives. Initially, captopril
was given at a dose of 6.25 mg orally every eight h and
titrated upwards to 75 mg every eight h as indicated to
maintain the optimal hemodynamics defined above. Oral
isosorbide dinitrate was then added at a dose of 10 mg every
eight h and titrated to achieve the hemodynamic goals
during which time the intravenous medication was de-
creased or discontinued. Hydralazine was then initiated, if
necessary, and titrated to optimize the hemodynamic mea-
surements. The dosing regimens established at the end of
therapy closely approximated the patients’ regimens at
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discharge from the hospital. The mean doses of captopril
before and after tailored therapy were 111.6 6 19.9 mg/day
and 137.5 6 15.8 mg/day, respectively (p 5 0.36), and the
mean doses of isosorbide dinitrate before and after therapy
were 32.7 6 13.1 mg/day and 49.1 6 10.9 mg/day,
respectively (p 5 0.03). Two subjects were started on
hydralazine during treatment. Table 1 shows the mean
hemodynamic values and patient weights before and after
medical therapy. Within 24 h of attaining these hemody-
namic goals on an oral regimen, patients returned to the
vascular laboratory for repeat vascular studies. All cardiac
and vasoactive medications were held for four h prior to the
study. The average number of days between studies was
7.8 6 3.4.
Statistical analysis. Data are expressed as mean 6 SE.
Both the peak flow rates after exercise and during ischemia-
induced reactive hyperemia, and the total volume repaid in
the 4 min following exercise or ischemia (an integration of
the flow rate vs. time curve), were analyzed. Comparisons of
group means for baseline demographics and limb blood flow
measurements between the control and heart-failure groups
were made by an unpaired, two-tailed Student t test with a
Bonferroni correction for multiple comparisons. Pretreat-
ment and posttreatment central and limb hemodynamic
measurements were compared using a paired, two-tailed
Student t test with a Bonferroni correction for multiple
comparisons. Statistical significance was accepted at the p #
0.05 level. The reported p-values are those calculated with
the Bonferroni correction.
RESULTS
Comparative findings between control and heart-failure
subjects. Prior to intensive medical therapy, resting calf
blood flow was significantly lower in the patients with heart
failure than in the healthy control subjects (1.0 6 0.1 vs.
1.6 6 0.1 ml/min/100 ml, p 5 0.004) (Fig. 1). Decompen-
sated heart-failure subjects also showed significantly lower
peak calf blood flow responses to exercise at both rates (30
cycles/min: 6.5 6 1.1 vs. 12.8 6 1.5 ml/min/100 ml, p 5
0.006; 60 cycles/min: 6.8 6 1.0 vs. 14.0 6 1.6 ml/min/100
ml, p 5 0.0016) (Fig. 1). In the 4 min following exercise,
total hyperemic volume was less in the heart-failure patients
than in control subjects (30 cycles/min: 5.9 6 0.7 vs. 9.3 6
1.8 ml/100 ml, p 5 0.04. 60 cycles/min: 7.1 6 1.1 vs.
11.9 6 1.1 ml/100 ml, p 5 0.011) (Fig. 2). Peak flow
following the ischemic stimulus was significantly lower in
heart-failure subjects (9.0 6 1.4 vs. 17.5 6 3.3 ml/min/100
ml, p 5 0.05) (Fig. 3). Mean total hyperemic volume after
ischemia was lower in heart-failure patients, but these data
did not reach statistical significance (5.2 6 0.6 vs. 7.9 6 1.5
ml/100 ml, p 5 0.22) (Fig. 3).
Effect of treatment on response to exercise. Baseline
blood flow did not increase significantly after intensive
medical therapy (pretreatment 1.0 6 0.1 vs. posttreatment
1.2 6 0.1 ml/min/100 ml, p 5 0.20) (Fig. 1). The peak calf
blood flow response to exercise, however, improved after
treatment (30 cycles/min: 6.5 6 1.1 to 9.6 6 1.6 ml/min/
Figure 1. Calf blood flow at rest and peak flow after 2 min of
isotonic exercise at 30 cycles/min (Ex30) and 60 cycles/min (Ex60)
in control subjects and heart-failure patients before (Pre-rx) and
after (Post-rx) medical therapy. *p # 0.05 compared to Pre-rx.
Figure 2. Calf hyperemic volume in the 4 min following isotonic
exercise at 30 cycles/min (Ex30) and 60 cycles/min (Ex60) in
control subjects and heart-failure patients before (Pre-rx) and after
(Post-rx) medical therapy. *p # 0.05 compared to Pre-rx.
Table 1. Resting Hemodynamics and Patient Weights Before
and After Therapy
Hemodynamic Parameter Pretreatment Posttreatment
Mean arterial pressure
(mm Hg)
83 6 2 74 6 2*
Heart rate (bpm) 89 6 4 86 6 5
Right atrial pressure
(mm Hg)
18 6 2 7 6 1*
Pulmonary wedge pressure
(mm Hg)
32 6 3 15 6 2*
Systemic vascular resistance
(dyneszszcm25)
1581 6 200 938 6 63*
Cardiac index (liter/min/m2) 2.01 6 0.20 2.87 6 0.22*
Weight (kg) 82.2 6 7.2 78.7 6 6.9*
*p # 0.05.
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100 ml, p 5 0.09; 60 cycles/min: 6.8 6 1.0 to 10.8 6 1.4
ml/min/100 ml, p 5 0.01) (Fig. 1). Total hyperemic volume
in the four min following exercise also increased after
treatment (30 cycles/min: 5.9 6 0.7 to 9.8 6 1.9 ml/100 ml,
p 5 0.09; 60 cycles/min: 7.1 6 1.0 to 12.3 6 2.1 ml/100 ml,
p 5 0.04) (Fig. 2). After adjustment for multiple compar-
isons, the response to exercise at the higher level, 60
cycles/min, was statistically significant. Posttreatment total
hyperemic response was comparable to that of the healthy
control subjects.
Effect of treatment on response to reactive hyperemia.
The peak calf reactive hyperemic response to ischemia
increased significantly after treatment (9.0 6 1.4 to 16.8 6
2.7 ml/min/100 ml, p 5 0.04). The mean total hyperemic
volume in the 4 min following cuff deflation was higher after
therapy, but this did not reach statistical significance (5.2 6
0.6 vs. 10.3 6 2.3 ml/100 ml, p 5 0.10) (Fig. 3). Responses
following treatment approached normal levels.
DISCUSSION
This study demonstrates that 1) lower extremity vascular
responsiveness to the metabolic stimuli of submaximal,
isotonic exercise and postischemic reactive hyperemia is
reduced in patients with decompensated heart failure, and
that 2) these responses improve after a brief period of
intensive medical therapy designed to normalize cardiac
filling pressures and systemic vascular resistance. These
findings support the rationale for aggressive treatment of
patients with heart failure, for favorable peripheral vasomo-
tor responses are likely to result.
In heart failure, exercise intolerance is related closely to
prognosis, yet limitation in activity does not correlate with
the left ventricular ejection fraction or the resting hemody-
namic indices of cardiac function (24). The failure of
dobutamine to enhance peak aerobic capacity despite an
immediate increase in cardiac output during exercise impli-
cates peripheral factors as important determinants of exer-
cise tolerance in heart failure (25–27). Peripheral vasomotor
reactivity may be an important contributor to patients’
exercise capacity (1,2), yet no prior study has investigated
the dynamic nature of the abnormality longitudinally, and
few studies have examined the regulation of leg blood flow
in patients with heart failure.
The finding in this study that heart-failure patients have
diminished vasomotor responses to metabolic stimuli sup-
ports the observations of several prior studies (1,2,9), but
differs from others (10,17,26). These apparently conflicting
observations may be due to the differing severity of illness or
to the fact that vascular function was measured in the leg
versus the arm. Jondeau et al. (1) has shown that, in the calf,
but not the forearm, blood flow response to ischemia is
related linearly to peak oxygen consumption in patients with
NYHA class II–III heart failure. Thus, compared to se-
verely symptomatic individuals, patients with mild heart
failure and higher peak oxygen consumption may have
near-normal limb vascular reactivity, particularly if the arm
is the target of the investigation. In normal healthy subjects,
deconditioning has been shown to reduce reactive hyper-
emic responses to ischemia (28), and may alter muscle
metabolism (29). As heart failure progresses, patients typi-
cally decrease their lower extremity physical activity, which
may lead to a cycle of deconditioning and further inactivity.
Therefore, the leg vascular responsiveness may become
impaired sooner than the arm during the course of the
disease.
In light of these differences in limb vascular reactivity, we
chose to investigate the leg in this metabolic study because
lower extremity exercise is essential for activities of daily
living, and is more often a source of symptoms for heart-
failure patients. In this study, 82% of the patients were in
NYHA class IV heart failure, and 18% in class III, indica-
tive of the marked severity of heart-failure symptoms in
these patients. All subjects had greater than six months’
duration of symptoms. Therefore, the abnormal responses
in this patient population are representative of lower ex-
tremity vascular function in patients with severe, chronic
heart failure.
Rapid improvement in vasoreactivity. We found that in
patients with heart failure, abnormal responses to important
metabolic stimuli improved to near normal levels following
a short period of intensive pharmacologic therapy. In the
present study, we used intensive, hemodynamically guided
medical therapy directed at normalization of right atrial
pressure, pulmonary capillary wedge pressure, and systemic
vascular resistance. The cardiac index also improved with
treatment, although not to normal levels. By contrast, the
forearm responses to reactive hyperemia initially do not
increase after cardiac transplantation despite immediate
improvement in cardiac function (20,30). Less intensive
therapy with diuretics alone may improve forearm conduc-
tance in a subset of patients, but not to normal levels (21).
Medical therapy, like that used in this study, has been
shown to improve functional status and exercise capacity in
Figure 3. Peak calf blood flow (left) after five min of arterial
occlusion in control subjects (Control), decompensated heart-
failure patients (Pre-rx), and the same patients after intensive
medical therapy (Post-rx). Total hyperemic volume (right) is
shown in the four min following arterial occlusion in the same
subject groups. *p # 0.05 compared to Pre-rx.
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patients with severe decompensated heart failure after 6 6 5
months (31). This clinical improvement may result in part
from the enhanced vasodilator response to exercise. Early
improvement in vasodilator responses to metabolic stimuli
may set the stage for improved exercise capacity with
resultant exercise reconditioning and, over time, with asso-
ciated neurohormonal changes (32). Whether the improved
vasoreactivity demonstrated in this study is sustained or
merely a short-term effect is not known.
Mechanisms of vascular dysfunction. Several potential
mechanisms may explain the abnormal vasomotor response
to metabolic stimuli in heart failure. Normal mediators of
blood flow following exercise and during reactive hyperemia
include nitric oxide (33–38), prostaglandins (39,40), aden-
osine (41–43), ATP-sensitive potassium channels (3,44,45),
and the sympathetic nervous system (46). Abnormalities in
one or more of these pathways could lead to the decreased
vascular reactivity observed in this study. In fact, Katz et al.
(14) found that regional inhibition of nitric oxide synthesis
decreased the forearm blood flow response to isometric
exercise in normal human controls, but not in heart-failure
patients, suggesting that nitric oxide-mediated vasodilation
during exercise is impaired in heart failure. The contribution
of other mechanisms to decreased vasodilator responsive-
ness in heart failure is not known.
Mechanisms of improvement in vascular reactivity may
include reduced vessel wall edema, decreased influence of
counter-regulatory vasoconstrictive substances, and en-
hanced local vasodilator function. Although none of our
patients had clinically demonstrable edema, therapy resulted
in an average diuresis of 3.5 6 0.5 liters, which could have
altered vascular wall sodium and water content, improving
vasodilator reserve (47–49). In normal subjects, increased
sympathetic tone leads to increased forearm vascular resis-
tance during reactive hyperemia, raising the possibility that
normalization of sympathetic tone in heart-failure patients
during therapy may improve vasodilation to an ischemic
stimulus (46).
Alternatively, the observed improvement in vascular re-
sponsiveness may be due to increased bioavailability of
endothelium-derived nitric oxide and, in some cases, the
addition of an exogenous nitric oxide donor, isosorbide
dinitrate, to the regimen (34,38). Endothelium-derived
nitric oxide may be affected by treatment, particularly with
angiotensin-converting enzyme inhibitors. In this study,
64% of patients were taking a higher dose of captopril at the
end of the study compared to the dose at the time of the
initial vascular measurements. This may have resulted in
increased bioavailability of nitric oxide due to decreased
bradykinin degradation (50,51) or decreased formation of
angiotensin II (52–54). A decrease in angiotensin II, sys-
temically or locally, over the course of therapy could
theoretically lead to decreased superoxide-mediated nitric
oxide inactivation (52), and, consequently, improved vascu-
lar responses to metabolic stimuli.
Conclusions. This study demonstrates that calf vascular
responsiveness to exercise is markedly abnormal in heart-
failure patients. Calf vascular reactivity to exercise, as well as
postocclusive reactive hyperemia, can be improved rapidly to
near normal levels with optimization of cardiac hemody-
namics using an aggressive medication regimen. The ability
to improve vasomotor responses to metabolic stimuli and
thus reverse the cycle of vascular dysfunction and decondi-
tioning in heart-failure patients may be crucial to long-term
improvement in exercise capacity and functional status in
this population.
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